In this section
@article{The:2021:10.1056/nejmoa2103417,
author = {The, REMAP-CAP and ACTIV-4a and and, ATTACC Investigators},
doi = {10.1056/nejmoa2103417},
journal = {New England Journal of Medicine},
pages = {777--789},
title = {Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19},
url = {http://dx.doi.org/10.1056/nejmoa2103417},
volume = {385},
year = {2021}
}
TY - JOUR
AB - BACKGROUNDThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.METHODSIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support–free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of −1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.RESULTSThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support–free days was 1 (interquartile range, −1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, −1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis.CONCLUSIONSIn critically ill patients with Covid-19, an initial strategy of therapeu
AU - The,REMAP-CAP
AU - ACTIV-4a
AU - and,ATTACC Investigators
DO - 10.1056/nejmoa2103417
EP - 789
PY - 2021///
SN - 0028-4793
SP - 777
TI - Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19
T2 - New England Journal of Medicine
UR - http://dx.doi.org/10.1056/nejmoa2103417
UR - https://www.nejm.org/doi/10.1056/NEJMoa2103417
UR - http://hdl.handle.net/10044/1/90874
VL - 385
ER -
For any questions related to the Centre, please contact:
Vasculitis Centre of Excellence Admin
VasculitisCoE@imperial.ac.uk
